BRD5648
Code | Size | Price |
---|
TAR-T10608-1mg | 1mg | £156.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10608-5mg | 5mg | £266.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10608-1mL | 1 mL * 10 mM (in DMSO) | £278.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10608-10mg | 10mg | £358.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10608-25mg | 25mg | £551.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10608-50mg | 50mg | £756.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10608-100mg | 100mg | £1,018.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
BRD5648 is an inactive (R)-enantiomer of BRD0705. BRD0705 is a GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM) and can be used in acute myeloid leukemia (AML) studies.
CAS:
2056261-42-6
Formula:
C20H23N3O
Molecular Weight:
321.424
Pathway:
Stem Cells; PI3K/Akt/mTOR signaling
Purity:
0.98
SMILES:
CC[C@]1(C2=CNNC2=NC2=C1C(=O)CC(C)(C)C2)c1ccccc1
Target:
GSK-3
References
1. Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431).
2. Scolnick Edward, et al. Preparation of substituted pyrazoloquinolinones as paralog-?selective inhibitors of GSK3 kinases. US20160375006A1